Collegium Pharma (COLL) Misses Q1 EPS by 3c, provides guidance

Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of $1.45, $0.03 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $144.9 million versus the consensus estimate of $147.54 million.

GUIDANCE:

Collegium Pharma sees FY2024 revenue of $580-595 million, versus the consensus of $581.7 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold